The Life Raft Group’s Patient Registry gives GIST patients an opportunity to contribute to finding a cure by sharing information on their medical status, treatments and side effects. This information is kept in a comprehensive [...]
A Life Raft Group meeting with Latin American representatives underscored barriers to the tissue bank program and proper diagnosis of GIST in the region while generating suggestions for ways of improving the system.
The fact is GIST is a rare disease and as a result researchers simply do not have enough GIST tissue samples to do the research needed to find a cure. “Too many people are still [...]
Innovative project will allow GIST researchers worldwide to access GIST tissue linked to patient-provided clinical histories. For more information on the GIST Tissue bank read the official press release.
This is part one of a two-part series on “KIT and PDGFRA kinase mutations in GIST: from A to Z”. In this newsletter, Dr. Heinrich will provide a background on the role of kinase mutations in GIST, focusing largely on the biological and clinical implications of these mutations. In part two (which will be featured in the July 2007 edition of the newsletter, following the special “Five-year anniversary” edition),
GIST patients with a particular genetic mutation are more likely to respond to Gleevec than those without the mutation, reported Dr. Michael C. Heinrich at one of the plenary sessions of the annual conference of the American Society of Clinical Oncology, held May 14-17 in Orlando, Florida.
